S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:SVA

Sinovac Biotech Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$6.47
0.00 (0.00 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.47
Now: $6.47
$6.47
50-Day Range
$6.47
MA: $6.47
$6.47
52-Week Range
$5.73
Now: $6.47
$8.75
VolumeN/A
Average VolumeN/A
Market Capitalization$639.88 million
P/E Ratio46.21
Dividend YieldN/A
Beta45.79
Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.
Read More
Sinovac Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SVA
CUSIPN/A
Phone86-10-5693-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$246.05 million
Cash Flow$0.50 per share
Book Value$3.56 per share

Profitability

Net Income$44.93 million

Miscellaneous

Employees1,043
Market Cap$639.88 million
Next Earnings Date11/20/2020 (Estimated)
OptionableOptionable

Receive SVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Sinovac Biotech (NASDAQ:SVA) Frequently Asked Questions

When is Sinovac Biotech's next earnings date?

Sinovac Biotech is scheduled to release its next quarterly earnings announcement on Friday, November 20th 2020.
View our earnings forecast for Sinovac Biotech
.

Has Sinovac Biotech been receiving favorable news coverage?

News articles about SVA stock have trended somewhat positive on Thursday, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sinovac Biotech earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Sinovac Biotech
.

Who are some of Sinovac Biotech's key competitors?

What other stocks do shareholders of Sinovac Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sinovac Biotech investors own include Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), AT&T (T), Tesla (TSLA), VIVUS (VVUS), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Micron Technology (MU) and TherapeuticsMD (TXMD).

Who are Sinovac Biotech's key executives?

Sinovac Biotech's management team includes the following people:
  • Wei Dong Yin, Chairman, President, CEO & Secretary
  • Nan Wang, Chief Financial Officer & VP-Business Development
  • Qiang Gao, Vice President-Research & Development
  • Xiao Mei Yin, Vice President-Sales & Marketing
  • Helen G. Yang, Investor Relations Contact

What is Sinovac Biotech's stock symbol?

Sinovac Biotech trades on the NASDAQ under the ticker symbol "SVA."

What is Sinovac Biotech's stock price today?

One share of SVA stock can currently be purchased for approximately $6.47.

How big of a company is Sinovac Biotech?

Sinovac Biotech has a market capitalization of $639.88 million and generates $246.05 million in revenue each year. Sinovac Biotech employs 1,043 workers across the globe.

What is Sinovac Biotech's official website?

The official website for Sinovac Biotech is www.sinovac.com.

How can I contact Sinovac Biotech?

Sinovac Biotech's mailing address is NO. 15 ZHI TONG ROAD ZHONGGUANCUN TECH PARK CHANGPING DISTR., BEIJING F4, 102200. The biopharmaceutical company can be reached via phone at 86-10-5693-1800 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.